KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Acquisitions & Divestments (2021 - 2025)

AbCellera Biologics (ABCL) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $119.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 40.79% year-over-year to $119.5 million, compared with a TTM value of $506.1 million through Dec 2025, down 46.04%, and an annual FY2025 reading of $506.1 million, down 46.04% over the prior year.
  • Change in Acquisitions & Divestments was $119.5 million for Q4 2025 at AbCellera Biologics, up from $83.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $306.5 million in Q1 2024 and bottomed at $18.1 million in Q4 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $169.6 million, with a median of $190.0 million recorded in 2025.
  • The sharpest move saw Change in Acquisitions & Divestments surged 410.99% in 2022, then tumbled 57.73% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $18.1 million in 2021, then soared by 410.99% to $92.4 million in 2022, then soared by 190.09% to $268.0 million in 2023, then fell by 24.67% to $201.9 million in 2024, then tumbled by 40.79% to $119.5 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ABCL at $119.5 million in Q4 2025, $83.1 million in Q3 2025, and $113.4 million in Q2 2025.